Substituted indoles and their use as integrin antagonists

Details Substituted indoles and their use as integrin antagonists Substituted indoles and their use as integrin antagonists

2007-07-10

2007-07-10

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S395000, C514S235200, C514S324000, C514S339000, C544S139000, C546S201000, C546S277400, C548S305100

Reexamination Certificate

active

11005294

ABSTRACT:
The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3and αvβ5integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3and αvβ5integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula:where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.

REFERENCES:
patent: 5223517 (1993-06-01), Muller et al.
patent: 5234942 (1993-08-01), Bernstein et al.
patent: 5290788 (1994-03-01), Stevens et al.
patent: 5741796 (1998-04-01), Hartman et al.
patent: 5744488 (1998-04-01), Cross et al.
patent: 5834454 (1998-11-01), Kitano et al.
patent: 5977100 (1999-11-01), Kitano et al.
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6184238 (2001-02-01), Takano et al.
patent: 2003/0045728 (2003-03-01), Wiesner et al.
patent: 0 623 607 (1994-11-01), None
patent: WO 97/06791 (1997-02-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 97/45137 (1997-12-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/13368 (1998-04-01), None
patent: WO 98/14192 (1998-04-01), None
patent: WO 99/30713 (1999-06-01), None
patent: WO 99/32150 (1999-07-01), None
patent: WO 99/43651 (1999-09-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Alfred Meijer {The Journal of Nutrition; Jun. 2003; 133; pp. 2057S-2062S}.
Alfred Meijer {The Journal of Nutrition; Jun. 2003; 133, pp. 2057S-2062S}.
Albelda, S.M., “Biology of Disease. Role of Integrins and Other Cell Adhesion Molecules in Tumor Progression and Metastasis,” Lab. Invest. 68:4-17, The United States and Canadian Academy of Pathology, Inc. (1993).
Albelda, S.M. et al., “Integrin Distribution in Malignant Melanoma: Association of the .beta..sub.3 Subunit with Tumor Progression,” Cancer Res. 50: 6757-6764, American Association for Cancer Research (1990).
Batcho, A. et al., “Indoles From 2-Methylnitrobenzenes by Condensation With Formamide Acetals Followed by Reduction: 4-Benzyloxyindole (1 H-Indole, 4-(phenylmethoxy)-),” in Organic Synthesis, Saucy, G. et al., Ed., John Wiley & Sons, New York, NY, pp. 214-225 (1985).
Boudreau, N. and Rabinovitch, M., “Developmentally Regulated Changes in Extracellular Matrix in Endothelial and Smooth Muscle Cells in the Ductus Arteriosus Maybe Related Intimal Proliferation,” Lab. Invest. 64:187-199, The United States and Canadian Academy of Pathology, Inc. (1991).
Brocke, S. et al., “Antibodies to CD44 and integrin.alpha..sub.4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment,” Proc. Natl. Acad. Sci. USA 96:6896-6901. The National Academy of Sciences (1999).
Brooks, P.C. et al., “Integrin .alpha..sub..nu..beta..sub.3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,” Cell 79:1157-1164, Cell Press (1994).
Brooks, P.C., “Integrin .alpha..nu..beta.3 : A Therapeutic Target,” DN&P 10:456-461, Prous Science (1997).
Brooks, P.C. et al., “Antiintegrin .alpha..nu..beta.3 blocks human breast cancer growth and angiogenesis in human skin,” J. Clin. Invest. 96:1815-1822, The American Society for Clinical Investigation, Inc. (1995).
Brooks, P.C. et al., “Requirement of Vascular Integrin .alpha..sub.nu..beta..sub.3 for Angiogenesis,” Science 264:569-571, American Association for the Advancement of Science (1994).
Cheresh, D.A., “Structure, function and biological properties of integrin of .alpha..sub..nu..beta..sub.3 on human melanoma cells,” Cancer Met. Rev. 10: 3-10, Kluwer Academic Publishers (1991).
Choi E.T. et al., “Inhibition of neointimal hyperplasia by blocking .alpha..sub..nu..beta..sub.3 integrin with a small peptide antagonist GpenGRGDSPCA,” J. Vasc. Surg. 19:125-134, The Society for Vascular Surgery and International Society for Cardiovascular Surgery (1994).
Corey, E.J. and Fuchs, P.L., “A Synthetic Method for Formyl .fwdarw. Ethynyl Conversion (RCHO .fwdarw. RC+CR'),” Tetrahedron Lett. 36:3769-3772, Pergamon Press (1972).
Enenstein, J. and Kramer, R.H., “Confocal Microscopic Analysis of Integrin Expression on the Microvasculature and its Sprouts in the Neonatal Foreskin,” J. Invest. Dermatol. 103:381-386, The Society for Investigative Dermatology, Inc. (1994).
Fisher, J.E. et al., “Inhition of Osteoclastic Bone Resorption In Vivo by Echistatin, an “Arginyl-Glycyl-Aspartyl” (RGD) -Containing Protein,” Endocrinology 132:1411-1413, The Endocrine Society (1993).
Friedlander, M. et al., “Definition of Two Anglogenic Pathways by Distinct .alpha..sub..nu. Integrins,” Science 270:1500-1520, American Association for the Advancement of Science (1995).
Gladson, C.L., “Expression of Integrin .alpha..nu..beta.3 in Small Blood Vessels of Glioblastoma Tumors,” J. Neuropathol. Exp. Neurol. 55:1143-1149, The American Association of Neuropathologists (1996.
Greene, T.W. and Wuts, P.G.M., “Special -NH Protective Groups. Protection for the Amino Group: Special -NH Protective Groups,” in Protective Groups in Organic Synthesis, 2nd edition, John Wiley and Sons, Inc., New York, pp. 267-287 and p. 331 (1991).
Greenspoon, N. et al., “Structural Analysis of Integrin Recognition and the Inhibiton of Integrin-Mediated Cell Functions by Novel Nonpeptidic Surrogates of the Arg-Gly-Asp Sequence,” Biochemistry 32:1001-1008, American Chemical Society (1993.
Hardan, I. et al., “Inhibiton of Metastatic Cell Colonization in Murine Lungs and Tumor-Induced Morbidity by Non-Peptidic Arg-Gly-Asp Mimetics,” Int. J. Cancer 55:1023-1028. Wiley-Liss, Inc. (1993).
Hendrickson, J.B. and Hussoin, MD. S., “Facite Dehydration of Activated Ketones to Alkynes,” Synthesis 3:217-221, Thieme Medical Publishers, Inc. (1989.
Hershkoviz, R. et al., “Inhibiton of CD4.sup.+ T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp,” Clin. Exp. Immunol. 95:270-276, Blackwell Scientific Publishers (1994).
Horton, M., “Current Status Review. Vitronectin receptor: tissue specific expression or adaption to culture?,” Int. J. Exp. Pathol. 71:741-759, Blackwell Scientific Publications (1990).
Hynes, R.O., “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion,” Cell 69:11-25, Cell Press (1992).
Juliano, R., “Signal transduction by integrins and its role in the regulation of tumor growth,” Cancer Met. Rev. 13:25-30, Kluwer Academic Publishers (1994).
Kaul, D.K. et al., “Monoclonal antibodies to .alpha..nu..beta.3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor,” Blood 95:368-374, The American Society of Hematology (Jan. 2000).
Ku, T.W. et al., “Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide,” J. Amer. Chem. Soc. 115:8861-8862, American Chemical Society (1993).
Marquardt, D. W., “An Algorithm for Least-Squares Estimation of Nonlinear Parameters,” J. Soc. Indust. Appl. Math. 11:431-441, Society for Industrial and Applied Mathematics (1963).
Mitsunobu, O., “The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products,” Synthesis 1:1-28, Georg Thieme Verlag (1981).
Nicosia, R.F. and Madri, J.A., “The Microvascular Extracellular Matrix. Develop

Affiliated with

Also associated with

Rating

Substituted indoles and their use as integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted indoles and their use as integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indoles and their use as integrin antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3804446